Pharvaris HAE drug shows faster symptom relief in Lancet study
Pharvaris' phase 3 study of deucrictibant IR for HAE attacks, published in The Lancet, met all endpoints, showing faster symptom relief and resolution than placebo. The drug was well-tolerated. FDA and EMA reviews are ongoing with decisions expected in 2027. According to the company, the study results support the drug's efficacy and safety.
How this was made
The 30-second read
Why it matters
Lancet publication of Phase 3 RAPIDe-3 with statistically significant faster onset and complete symptom resolution versus placebo strengthens the clinical evidence package for regulatory review.
Market read
Traders can reassess approval odds and timeline risk based on newly published Phase 3 efficacy and safety evidence, with explicit FDA and EMA review status.
What to watch
The article does not provide effect size on clinically meaningful endpoints beyond timing metrics, nor does it discuss comparative positioning versus existing HAE standards or payer/access considerations.
Background
Pharvaris is developing deucrictibant in extended-release (prophylaxis) and immediate-release (on-demand) formulations for hereditary angioedema (HAE) attacks.
Ticker impact
Pharvaris reported Phase 3 RAPIDe-3 Lancet publication showing deucrictibant IR met primary and all 11 secondary endpoints with faster symptom relief vs placebo.
Likely upward bias as traders price in improved clinical credibility ahead of FDA review milestones.
The article discloses specific Phase 3 timing outcomes, endpoint success, and absence of safety signals, plus stated FDA target action date (Apr 23, 2027) and EMA review.
Market effects
Reinforces the bradykinin B2 antagonist on-demand HAE treatment efficacy narrative, potentially supporting sentiment across rare-disease biotech with similar mechanisms.
Limited direct regional impact; primarily affects US-listed rare-disease biotech risk appetite.
EMA review progress and Lancet publication can influence global investor sentiment for HAE therapeutics.
Counterpoint
Despite positive Phase 3 results, approval timing and label details remain uncertain, and the market may already be positioned for efficacy given the ongoing FDA review.
Key entities
- companyPharvaris
NASDAQ-listed developer of deucrictibant for hereditary angioedema; subject of the Phase 3 RAPIDe-3 results.
- drugdeucrictibant immediate-release (IR)
Oral 20 mg bradykinin B2 receptor antagonist capsule evaluated for on-demand treatment of HAE attacks.
- clinical_trialRAPIDe-3
Randomized, double-blind, placebo-controlled crossover Phase 3 study; results published in The Lancet.
- regulatorFDA
Regulatory body reviewing a New Drug Application for deucrictibant IR with a stated target action date of April 23, 2027.
- regulatorEuropean Medicines Agency (EMA)
Reviewing a Marketing Authorization Application for deucrictibant IR.
